Abstract：
UNASSIGNED: Information related to herpes simplex virus 1 and 2 (HSV-1 and 2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) seroprevalence in France is either lacking, incomplete, or outdated, despite their public health burden.
UNASSIGNED: We used routinely collected serological data between 2018 and 2022 to estimate HSV-1, HSV-2, VZV, EBV, and CMV seroprevalence in France. To account for demographic differences between our analytic samples and the French population and get estimates for sparsely sampled districts and age classes, we used a multilevel regression and poststratification approach combined with Bayesian model averaging via stacking weights.
UNASSIGNED: The observed seroprevalence (number of positive tests/number of tests) were 64.6% (93,294/144,424), 16.9% (24,316/144,159), 93.0% (141,419/152,084), 83.4% (63,199/75, 781), and 49.0% (23,276/47,525), respectively, for HSV-1, HSV-2, VZV, EBV, and CMV. Between 2018 and 2022, France had a model-based average (equal-tailed interval at 95%) expected seroprevalence equal to 61.1% (60.7,61.5), 14.5% (14.2,14.81), 89.5% (89.3,89.8), 85.6% (85.2,86.0), and 50.5% (49.3,51.7), respectively, for HSV-1, HSV-2, VZV, EBV, and CMV infections. We found an almost certain lower expected seroprevalence in Metropolitan France than in overseas territories for all viruses but VZV, for which it was almost certainly greater. The expected seroprevalences were likely greater among females for all viruses.
UNASSIGNED: Our results relied on the assumption that individuals were sampled at random conditionally to variables used to build the poststratification table.
UNASSIGNED: The analysis highlights spatial and demographic patterns in seroprevalence that should be considered for designing tailored public health policies.
UNASSIGNED: We used routinely collected serological data between 2018 and 2022 to estimate HSV-1, HSV-2, VZV, EBV, and CMV seroprevalence in France. To account for demographic differences between our analytic samples and the French population and get estimates for sparsely sampled districts and age classes, we used a multilevel regression and poststratification approach combined with Bayesian model averaging via stacking weights.
UNASSIGNED: The observed seroprevalence (number of positive tests/number of tests) were 64.6% (93,294/144,424), 16.9% (24,316/144,159), 93.0% (141,419/152,084), 83.4% (63,199/75, 781), and 49.0% (23,276/47,525), respectively, for HSV-1, HSV-2, VZV, EBV, and CMV. Between 2018 and 2022, France had a model-based average (equal-tailed interval at 95%) expected seroprevalence equal to 61.1% (60.7,61.5), 14.5% (14.2,14.81), 89.5% (89.3,89.8), 85.6% (85.2,86.0), and 50.5% (49.3,51.7), respectively, for HSV-1, HSV-2, VZV, EBV, and CMV infections. We found an almost certain lower expected seroprevalence in Metropolitan France than in overseas territories for all viruses but VZV, for which it was almost certainly greater. The expected seroprevalences were likely greater among females for all viruses.
UNASSIGNED: Our results relied on the assumption that individuals were sampled at random conditionally to variables used to build the poststratification table.
UNASSIGNED: The analysis highlights spatial and demographic patterns in seroprevalence that should be considered for designing tailored public health policies.
摘要：
■与单纯疱疹病毒1和2（HSV-1和2）有关的信息，水痘-带状疱疹病毒（VZV），EB病毒(EBV)法国缺乏巨细胞病毒（CMV）血清阳性率，不完整,或过时,尽管他们的公共卫生负担。
■我们使用2018年至2022年之间常规收集的血清学数据来估计HSV-1，HSV-2，VZV，EBV,和法国的CMV血清阳性率。为了解释我们的分析样本和法国人口之间的人口统计学差异，并获得对稀疏样本地区和年龄组的估计，我们使用了多级回归和后分层方法，并结合了通过堆叠权重进行贝叶斯模型平均。
■观察到的血清阳性率（阳性测试次数/测试次数）为64.6％（93,294/144,424），16.9%（24,316/144,159），93.0%（141,419/152,084），83.4%（63,199/75,781），和49.0%（23,276/47,525），分别,对于HSV-1，HSV-2，VZV，EBV,CMV。在2018年至2022年之间，法国的基于模型的平均（等尾间隔为95％）预期血清阳性率等于61.1％（60.7,61.5），14.5%（14.2,14.81），89.5%（89.3,89.8），85.6%（85.2,86.0），和50.5%(49.3,51.7)，分别,对于HSV-1，HSV-2，VZV，EBV,和CMV感染。我们发现，除了VZV之外，法国大都会地区的所有病毒的预期血清阳性率几乎都比海外地区低，几乎肯定更大。对于所有病毒，女性的预期血清感染率可能更高。
■我们的结果依赖于这样的假设，即个体被随机有条件地抽样到用于构建后分层表的变量。
■该分析突出了血清阳性率的空间和人口模式，应在设计量身定制的公共卫生政策时予以考虑。
■我们使用2018年至2022年之间常规收集的血清学数据来估计HSV-1，HSV-2，VZV，EBV,和法国的CMV血清阳性率。为了解释我们的分析样本和法国人口之间的人口统计学差异，并获得对稀疏样本地区和年龄组的估计，我们使用了多级回归和后分层方法，并结合了通过堆叠权重进行贝叶斯模型平均。
■观察到的血清阳性率（阳性测试次数/测试次数）为64.6％（93,294/144,424），16.9%（24,316/144,159），93.0%（141,419/152,084），83.4%（63,199/75,781），和49.0%（23,276/47,525），分别,对于HSV-1，HSV-2，VZV，EBV,CMV。在2018年至2022年之间，法国的基于模型的平均（等尾间隔为95％）预期血清阳性率等于61.1％（60.7,61.5），14.5%（14.2,14.81），89.5%（89.3,89.8），85.6%（85.2,86.0），和50.5%(49.3,51.7)，分别,对于HSV-1，HSV-2，VZV，EBV,和CMV感染。我们发现，除了VZV之外，法国大都会地区的所有病毒的预期血清阳性率几乎都比海外地区低，几乎肯定更大。对于所有病毒，女性的预期血清感染率可能更高。
■我们的结果依赖于这样的假设，即个体被随机有条件地抽样到用于构建后分层表的变量。
■该分析突出了血清阳性率的空间和人口模式，应在设计量身定制的公共卫生政策时予以考虑。
